- Home
- TRMB vs MRNA Comparison
TRMB vs MRNA Comparison
Compare TRMB & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMB
- MRNA
- Stock Information
- Founded
- TRMB 1978
- MRNA 2010
- Country
- TRMB United States
- MRNA United States
- Employees
- TRMB 12700
- MRNA N/A
- Industry
- TRMB Industrial Machinery/Components
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRMB Industrials
- MRNA Health Care
- Exchange
- TRMB Nasdaq
- MRNA Nasdaq
- Market Cap
- TRMB 17.8B
- MRNA 16.5B
- IPO Year
- TRMB 1990
- MRNA 2018
- Fundamental
- Price
- TRMB $72.36
- MRNA $40.20
- Analyst Decision
- TRMB Buy
- MRNA Hold
- Analyst Count
- TRMB 7
- MRNA 18
- Target Price
- TRMB $82.29
- MRNA $79.50
- AVG Volume (30 Days)
- TRMB 1.3M
- MRNA 7.6M
- Earning Date
- TRMB 02-10-2025
- MRNA 11-07-2024
- Dividend Yield
- TRMB N/A
- MRNA N/A
- EPS Growth
- TRMB 342.93
- MRNA N/A
- EPS
- TRMB 5.97
- MRNA N/A
- Revenue
- TRMB $3,632,300,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- TRMB N/A
- MRNA N/A
- Revenue Next Year
- TRMB N/A
- MRNA N/A
- P/E Ratio
- TRMB $12.21
- MRNA N/A
- Revenue Growth
- TRMB N/A
- MRNA N/A
- 52 Week Low
- TRMB $48.60
- MRNA $35.80
- 52 Week High
- TRMB $76.97
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- TRMB 53.98
- MRNA 39.50
- Support Level
- TRMB $72.53
- MRNA $41.06
- Resistance Level
- TRMB $74.98
- MRNA $44.38
- Average True Range (ATR)
- TRMB 1.51
- MRNA 2.43
- MACD
- TRMB -0.52
- MRNA 0.29
- Stochastic Oscillator
- TRMB 10.00
- MRNA 16.93
About TRMB Trimble Inc.
Trimble Inc provides a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has four reportable segments: Buildings and Infrastructure, Geospatial, Resources and Utilities, and Transportation. The company generates the majority of its revenue from the Buildings and Infrastructure segment, which primarily serves customers working in architecture, engineering, construction, design, asset management, operations, and maintenance.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.